Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

42 2,080

Shareholders' equity 2,053 1,866

Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA

To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company is providing the supplemental financial information contained below to reflect (1) the adjusted earnings per share effect of certain unusual or infrequent charges or benefits that were taken or received in the quarter ended March 31, 2008, and (2) the calculation of EBITDA for each period presented.

Adjusted earnings per share and EBITDA are non-GAAP financial measures. The Company is providing this information, however, because it believes that such information is useful to both management and investors in that it facilitates analysis by both management and investors in evaluating the Company's performance and trends. The presentation of this additional information is not meant to be considered in isolation of, or as a substitute for, results prepared in accordance with GAAP.

Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data

(in millions, except per share amounts)

Three Months Ended March 31, 2008

Adjusted

GAAP Adjustments Earnings

Revenues:

Product sales $565 - $565

Alliance and

development revenue 32 - 32

Other revenue 11 (5) (b) 6

Total revenues 608 (5) 603

Costs and expenses:

Cost of sales 275 (55) (b),(c),(d),(f) 220

Selling, general and

adm
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Mechanicsburg, Pa (PRWEB) May 20, 2013 ... controller with ramp/soak capabilities. The 5R6-900 benchtop controller ... enclosure, the device can be plugged into the wall ... own power supply. This distinctive detail makes the device ... , The laboratory temperature controller can also be ...
(Date:5/20/2013)... Today, at the American Psychiatric Association (APA) ... James McGough , M.D., M.S., principal investigator ... for Neuroscience and Human Behavior and David ... of California Los Angeles (UCLA), and director of clinical ... ADHD at UCLA, presented the results of a Phase ...
(Date:5/20/2013)... DIEGO , May 20, 2013  Dr. ... field of nucleic acid research, recently launched a new ... In with Zon ( zon.trilinkbiotech.com ), focuses on what,s ... include interviews with industry thought leaders, discussions of research ... and more. Dr. Zon (PhD Princeton ...
(Date:5/20/2013)... 20, 2013 With bed bugs' presence come ... although bed bugs need to be eliminated, one must make ... a person's health. And so to help bed bug sufferers ... get rid of bed bugs without using harmful pesticides. ... spray it called Bed Bug Bully. , According to My ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
... ,Arpida Ltd (SWX: ARPN) presented a large body ... iclaprim at the 47th annual Interscience,Conference on Antimicrobial ... major scientific conference where thousands of scientists and,clinicians ... the latest,developments in the field of infectious diseases. ...
... bacterial contamination in ... platelets, WORCESTER, ... for detecting bacterial contaminants in,blood cells and tissue, has received 510 (k) ... Administration (FDA). This provides,Verax authorization to market the device, which cuts the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 4Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 2Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 3
(Date:5/20/2013)... of Minnesota Medical School researchers from the Masonic Cancer ... Brain Tumor Program, have developed a new mouse model ... them to discover new genes and gene pathways driving ... this week in the journal Nature Genetics . ... the lab of David Largaespada, Ph.D., professor in the ...
(Date:5/20/2013)... 20, 2013) - A novel vaccine study ... groundbreaking research that will be unveiled at the American ... The meeting takes place Monday, May 20 - Wednesday, ... Marina. , "The main goal of a vaccine ... a pathogen that causes the disease", explained Dr. Hemachand ...
(Date:5/19/2013)... Scientists at the University of California, Davis have engineered ... need for light. They report their findings today ... for Microbiology. , "In this work, we used synthetic ... on carbon dioxide and light energy for growth) cyanobacterial ... says Jordan McEwen, the lead researcher on the study. ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... University have developed a technique that uses a ... particles within seconds, representing a potential new tool ... nanoassembly. The technique, called rapid electrokinetic patterning, ... the patterns can be more quickly and easily ...
... Conn.Organizations in the United States that are at the ... not adapting enough to the dangers posed by rising ... half century of climate change that has already significantly ... widespread ecological and hydrological impacts, and despite a near ...
... (DFG, German Research Foundation) will launch ten new Collaborative ... next four years with a total of approximately 90 ... Centres will study the origins of diseases caused by ... and the human skin. Other topics include the optimisation ...
Cached Biology News:New holographic method could be used for lab-on-a-chip technologies 2New holographic method could be used for lab-on-a-chip technologies 3New holographic method could be used for lab-on-a-chip technologies 4Most US organizations not adapting to climate change 2Most US organizations not adapting to climate change 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 2From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 4From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 5From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 6From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 7
...
...
... The greater incorporation of Br-dUTP results in ... detected using a fluorescein-labeled anti-BrdU antibody. ... the kit to counterstain the total DNA. ... resulting in improved detection than found by ...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Biology Products: